Mesothelioma and Radical Surgery 2 (MARS 2): protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma
Introduction Mesothelioma remains a lethal cancer. To date, systemic therapy with pemetrexed and a platinum drug remains the only licensed standard of care. As the median survival for patients with mesothelioma is 12.1 months, surgery is an important consideration to improve survival and/or quality...
Saved in:
Similar Items
-
Pharmacokinetics of Hyperthermic Intrathoracic Chemotherapy following Pleurectomy and Decortication
by: Paul H. Sugarbaker, et al.
Published: (2012-01-01) -
Simulation and Test of Key Decorticating Components of Spiral Ramie Decorticator
by: Wenlong Zheng, et al.
Published: (2025-01-01) -
Malignant Pleural Mesothelioma. Case Report and Literature Review
by: Samuel Sánchez Sánchez, et al.
Published: (2020-10-01) -
Fibrothorax and Severe Lung Restriction Secondary to Lupus Pleuritis and Its Successful Treatment by Pleurectomy
by: Sat Sharma, et al.
Published: (2002-01-01) -
Functional and Radiological Outcome Analysis of Osteoperiosteal Decortication Flap in Nonunion of Tibia
by: Vineet Kumar, et al.
Published: (2021-01-01)